Hungarian Drug Prices, Pharmacy Privatization

15 January 1996

Retail medicine prices in Hungary were increased by 40% on January 1 following a rise in consumption tax, reports MTI Econews. producer prices of drugs increased by only 14%.

Meantime, the Budapest City Council hopes to make 2.5-3 billion forint ($18-$21.5 million) from the privatization of its 189 city pharmacies, with completion expected by June 30, reports MTI Econews. The Council will receive the proceeds from the sale of the pharmacies' real estate and assets, with revenue from their stocks, estimated at about 1 billion forint, going to the Pharmafontana company which manages the pharmacies and will continue to do so until they are sold.

At the start of 1996 97 pharmacies had been offered in 10 package deals, with sales approved for 64 and sales of 57 completed. Loans to purchasers are being provided by Japanese and german lenders. New owners must operate the pharmacies for at least five years, and the Council has the right to repurchase them for a further five years after that.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight